Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.46 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17772171 | 0.87 | KDM1A (0.47) | KDM1ARCOR1MAOBMAOARIPK1 | |
| SCHEMBL18324650 | 0.81 | KDM1A (0.42) | KDM1ARCOR1NTRK1JAK2MAOB | |
| SCHEMBL4289056 | 0.81 | MAOB (0.45) | KDM1ARCOR1NTRK1JAK2MAOB | |
| SCHEMBL4096537 | 0.78 | KDM1A (0.40) | KDM1ARCOR1NTRK1JAK2MAOB | |
| SCHEMBL454721 | 0.77 | NTRK1 (0.43) | KDM1ARCOR1NTRK1JAK2MAOB | |
| SCHEMBL454720 | 0.77 | NTRK1 (0.43) | KDM1ARCOR1NTRK1JAK2MAOB | |
| SCHEMBL17772162 | 0.76 | RIPK1 (0.50) | KDM1ARCOR1MAOBMAOARIPK1 | |
| SCHEMBL19275745 | 0.74 | RIPK1 (0.58) | MAOBMAOARIPK1KDM4E | |
| SCHEMBL25315864 | 0.73 | RIPK1 (0.45) | KDM1ARCOR1NTRK1JAK2MAOB | |
| SCHEMBL18783105 | 0.72 | LMNA (0.56) | KDM1ARCOR1NTRK1MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011604-B2 | Method of treatment using substituted imidazo[1,2b]pyridazine compounds | ARRAY BIOPHARMA, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-9682979-B2 | Substituted pyrazolo [1,5-A] pyrimidine compounds as TRK kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| EP-2350071-B1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2014-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011604-B2 | Method of treatment using substituted imidazo[1,2b]pyridazine compounds | COL2A1, COL1A1, IFNAR1 | KDM1A 967/4885RCOR1 2900/4885NTRK1 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.